“We are focused on the advancement of BDTX-1535 for the treatment of patients with EGFRm NSCLC and look forward to providing clinical updates on our Phase 2 trial for both newly diagnosed patients and patients with relapsed/refractory EGFRm NSCLC in the first quarter of 2025,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics (BDTX). “We also look forward to sharing feedback on a registrational path in relapsed/refractory EGFRm NSCLC following a meeting planned with the FDA in the first quarter of 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- BDTX Earnings this Week: How Will it Perform?
- 3 Best Stocks to Buy Now, 10/8/2024, According to Top Analysts
- Black Diamond Therapeutics Restructures to Focus on Oncology Lead Program
- Black Diamond CFO Fang Ni, CPO Elizabeth Montgomery to depart in restructuring
- Black Diamond Therapeutics price target raised to $18 from $15 at Stifel